drugset / Trial / NCT07356466

Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07356466

Phase 0 Enrolling by invitation 100 enrolled Fujian Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the objective response rate (ORR) of Pembrolizumab combined with Lenvatinib and SOX compared with SOX alone in the treatment of patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.

Timeline

Start
2025-05-01
Primary completion
2027-04-30
Completion
2030-04-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule
Subject Oxaliplatin Small molecule
Subject Pucotenlimab Monoclonal antibody
Subject S-1 Small molecule

Indications